The Efficacy of Pantothenic Acid As a Modifier of Body Composition in a Porcine Model of Obesity Development

Total Page:16

File Type:pdf, Size:1020Kb

The Efficacy of Pantothenic Acid As a Modifier of Body Composition in a Porcine Model of Obesity Development Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1-1-2004 The efficacy of pantothenic acid as a modifier of body composition in a porcine model of obesity development Carey Ann Baldwin Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Recommended Citation Baldwin, Carey Ann, "The efficacy of pantothenic acid as a modifier of body composition in a porcine model of obesity development" (2004). Retrospective Theses and Dissertations. 20349. https://lib.dr.iastate.edu/rtd/20349 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. The efficacy of pantothenic acid as a modifier of body composition in a porcine model of obesity development by Carey Ann Baldwin A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Animal Nutrition Program of Study Committee: Tim Stahly, Major Professor Paul Flakoll Chad Stahl Iowa State University Ames, Iowa 2004 Copyright© Carey Ann Baldwin, 2004. All rights reserved. 11 Graduate College Iowa State University This is to certify that the master's thesis of Carey Ann Baldwin has met the thesis requirements of Iowa State University Signatures have been redacted for privacy 111 TABLE OF CONTENTS ACKNOWLEDGEMENTS Vl ABSTRACT Vll CHAPTER 1. GENERAL INTRODUCTION 1 Introduction 1 Thesis Organization 2 Literature Cited 2 CHAPTER 2. LITERATURE REVIEW 5 Body Composition and Tissue Accretion 5 Adipose Tissue Accretion 5 Depot Differences in Adipose Tissue Accretion 6 Energy Expenditure and Substrate Oxidation 7 Maintenance Requirements 9 Feed Restriction 10 Muscle Metabolism 11 Endocrine Function of Adipose Tissue 11 Other Factors Affecting Tissue Accretion 12 Glucose-Fatty Acid Cycle 12 Direct Fat Deposition 13 Lipogenesis 14 Fatty Acyl Synthase 14 De Novo Lipogenesis 15 Acetyl-CoA Carboxylase 15 Lipolysis 16 Peroxisomal Fatty Acid Beta-Oxidation 16 Acyl-CoA Oxidase 17 Species Differences in Fat Metabolism 17 lV Obesity 18 Obesity Characteristics 18 Obesity Complication - Insulin Resistance 19 Animal Models of Obesity 20 Dietary Fat 22 Dietary Carbohydrate 23 Pantothenic Acid 24 Pantothenic Acid Sources 24 Pantothenic Acid Requirements 25 Pantothenic Acid Deficiency 26 Pantothenic Acid Toxicity 27 Methods of Predicting Pantothenic Acid Levels 27 Pantothenic Acid in the Body 27 The Metabolic Role of Pantothenic Acid 28 The Role of Pantothenic Acid in Body Composition 30 Body Composition Measures 31 Dual-Energy X-Ray Absorptiometry 32 Proximate Analysis (Chemical Composition) 32 Subcutaneous Backfat Measures 33 Real-Time Polymerase Chain Reaction 33 Summary/Objectives 36 Literature Cited 37 CHAPTER 3. DUAL-ENERGY X-RAY ABSORPTIOMETRY FOR DETERMINATION OF BODY COMPOSITION IN PORCINE MODEL OF OBESITY DEVELOPMENT Abstract 49 Introduction 49 Materials and Methods 50 Results and Discussion 54 v Literature Cited 59 CHAPTER 4. EFFICACY OF P ANTOTHENIC ACID AS A MODIFIER OF BODY COMPOSITION IN A PORCINE MODEL OF OBESITY DEVELOPMENT Abstract 64 Introduction 64 Materials and Methods 65 Results and Discussion 69 Literature Cited 73 CHAPTERS. GENERALSUMMARY 91 VI ACKNOWLEDGEMENTS I would first like to recognize my Major Professor, Dr. Tim Stahly, for the opportunities, guidance and support he has provided throughout my graduate education at Iowa State University. I would also like to thank my committee members, Dr. Chad Stahl and Dr. Paul Flakoll, for their input and contributions to this thesis. In addition, I would like to thank the farm crew (Dan Johnson, Robert Tripp, Harlan Moody and John Simonson) for their humor and assistance with numerous diet mixings. I thank Kyle Dunn, Arlie Penner, Dongyan Wang, Sherri Swanton, and Brody Laabs for help with data collection and analysis. I could not have moved those pigs without your help. I would also like to thank Leslie Lincoln, Monica Perez-Garcia, Martha Jeffrey, and Laura Hittmeier for helping me to analyze laboratory samples. We have learned a lot along the way. I thank the Iowa State University Meats Laboratory for pig processing, Reid Landes for assistance with statistical analysis, and Kathy Hanson for DEXA analysis. Your contributions made the work a lot easier. For their friendship, assistance, and knowledge in countless areas, I thank Rich Clayton and Dr. Trevor Lutz. I am also very appreciative to the other members of the Molecular and Animal Nutrition Group for their support and numerous contributions to my graduate education. I give credit to Dr. Rodney Johnson and fellow Illini in the Laboratory oflntegrative Biology for inspiring me to pursue a graduate education. It is, however, the constant love and support of my husband, parents, family and friends that has allowed me to succeed in the · pursuit of my dreams. Your patience, interest and encouragement have kept me going. vu ABSTRACT The accuracy and precision of body composition measurement by Dual-Energy X-ray Absorptiometry (DEXA) and the efficacy ofpantothenic acid (PA) as a modifier of body composition in a pig model of obesity development were determined. Heavy weight barrows at six months of age were adjusted to a high fat basal diet with a calorie mix representative of that typically consumed by adults in the US (34 % of calories from fat) that provided daily dietary caloric intakes equivalent to 1.8 times their estimated body maintenance (110 kcal ME/ BW kg ·75 I day) needs based on the weekly mean BW of each animal. The basal diet provided PA in an amount that met or exceeded the current estimated needs of pigs and humans. This diet was expected to cause an obese state over a period of 144 d. At slaughter, the weights and tissue contents (fat, lean and bone mineral) of two body depots (carcass and internal organs) were evaluated by gravimetric, DEXA, and chemical measures. Subcutaneous carcass fat and longissimus muscle area measurements were also performed. The precision and accuracy of the DEXA estimates of the weight and tissue content of the two body depots were evaluated in thirty-three pigs (133-265 kg). DEXA scanning accurately estimated the carcass depot weight (+2 %) relative to that determined by gravimetric weighing. DEXA underestimated the fat tissue contents of the two depots (-19 and -26 %) and overestimated the lean tissue contents (13 and 27 %) relative to those estimated from chemical analysis of the fat and protein contents of the depots. However, DEXA precisely detected changes in carcass and organ depot weights (R2= .99, .99, respectively) and less precisely predicted changes in the depot's chemically determined fat (R2 = .95, .73) and protein content (R2= .88, .84). Specifically, for each 1 kg change in carcass and organ depot weights, DEXA predicted the changes with a 95 % confidence (2 SE of estimate) within± .008 and .026 kg, respectively. For each 1 kg change in the carcass and organ depot's chemically determined fat content, DEXA predicted the change within± .092 and .338 kg, respectively. The efficacy of supplemental PA (0, 80, 800, 8000 ppm) as a modifier of body composition was determined on pigs (17/treatment) that were randomly allotted to dietary Vlll treatment by body weight and date on test (block). Pigs with an initial BW and fat content of 154 kg and 27 %, respectively, accrued 73 kg ofBW of which 48 % was body fat in the obesity development model. BW gains, BW gain/feed ratios, feed intake, and subcutaneous backfat depths were not altered by PA additions. Whole body fat tissue content responded quadratically to increasing PA additions. Body fat percentage was reduced by .9 percentage units by the 80 ppm added PA and increased by 1.6 and 1.1 percentage units by the 800 and 8000 ppm added PA. Hepatic acetyl-CoA carboxylase, acyl-CoA oxidase, and fatty acid synthetase mRNA expression did not differ between the 0 and 8000 ppm supplemented PA diets. Based on these data, DEXA precisely predicts weight and tissue content in different body depots, and PA is not an efficient modifier of body composition in a porcine model of obesity development induced by a high fat dietary regimen. 1 CHAPTER!. GENERAL INTRODUCTION Introduction Obesity is becoming a worldwide epidemic, affecting both children and adults. The WHO (2003) states that more than one billion adults are overweight with at least 300 million of them being obese. In the U.S., 30.6% of adults were reported as obese in 2000-2001, with 16.5% of children being overweight (CSREES, 2004). The increasing incidence of the disease seems to be due in great part to more sedentary lifestyles coupled with consumption of more energy and nutrient-dense diets. Although some people may be more genetically prone to obesity, environmental factors seem to assist in its development, for its occurrence tends to be greater in urban areas and in individuals previously experiencing sub-optimal levels of nutrition (WHO, 1997; Frisancho, 2003; Jang et al., 2003). Obesity poses a major risk for chronic diseases such as type 2 diabetes, cardiovascular disease, hypertension, stroke and certain forms of cancer (WHO, 2003). Worldwide attention has shifted towards research in obesity prevention and therapy as health care costs skyrocket. Pantothenic acid is involved as a cofactor in lipid, carbohydrate, and protein metabolism. It has been shown to provide protective effects against radioactive and oxidative damage (Slyshenkov et al., 2004), to have a therapeutic role in wound healing (Weimann and Hermann, 1999), to stimulate blastocyst development and be beneficial to fetus survivability (McKieman and Bavister, 2000). Pantothenic acid and its derivatives have gained recently gained attention for their roles in lipid metabolism.
Recommended publications
  • The Role of Nutritional Therapies in the Care Of
    © Michael Ash BSc DO ND F.DipION 2010 4/29/2010 'The role of Nutritional Therapy in the care of individuals with cardiovascular related problems' Michael Ash BSc (Hons) DO ND F DipION mBANT NTCC Osteopath Naturopath Nutritional Therapist Researcher Author Nutritional Therapy • A Functional Medicine approach to optimise outcomes, ease of engagement and compliance. • 8 Practical strategies & how to avoid common pitfalls. • Interaction of the immune system with the heart. • GastroCentric Perspective. • How food selection can provide a multi faceted benefit. • Supplements of benefit. 1 © Michael Ash BSc DO ND F.DipION 2010 4/29/2010 Client Overview Goals Determine their aims and outcomes – the purpose of the plan is to support the patients goals with evidence based strategies Identify realistic goals, obtain agreement that these are achievable and describe plan ASSESMENT ANTECEDENTS TRIGGERS Medical history review and systems analysis assess the: MEDIATORS Antecedents: Sex, Age, Genetics, Lifestyle, Experiences, Trauma, Childhood, Stress, etc. Triggers: Events that initiate illness or symptoms – stress, infection, environmental toxins, food. etc. – look to see if they can be removed or controlled Mediators: Cytokines, prostaglandins, free radicals, neurotransmitters, fear, personal value, behavioural conditioning, poverty, etc. Evolutionary Nutritional Therapy • In physiology, foetal nutritional stress appears to flip an evolved switch that sets the body into a state that protects against starvation. • When these individuals encounter modern diets, they respond with the deadly metabolic syndrome of obesity, hypertension, and diabetes. • Barker DJ, Eriksson JG, Forsén T, Osmond C.Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002 Dec;31(6):1235-9.
    [Show full text]
  • The Effect of Vitamin Supplementation on Subclinical
    molecules Review The Effect of Vitamin Supplementation on Subclinical Atherosclerosis in Patients without Manifest Cardiovascular Diseases: Never-ending Hope or Underestimated Effect? Ovidiu Mitu 1,2,* , Ioana Alexandra Cirneala 1,*, Andrada Ioana Lupsan 3, Mircea Iurciuc 4 , 5 5 2, Ivona Mitu , Daniela Cristina Dimitriu , Alexandru Dan Costache y , Antoniu Octavian Petris 1,2 and Irina Iuliana Costache 1,2 1 Department of Cardiology, Clinical Emergency Hospital “Sf. Spiridon”, 700111 Iasi, Romania 2 1st Medical Department, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania 3 Department of Cardiology, University of Medicine, Pharmacy, Science and Technology, 540139 Targu Mures, Romania 4 Department of Cardiology, University of Medicine and Pharmacy “Victor Babes”, 300041 Timisoara, Romania 5 2nd Morpho-Functional Department, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania * Correspondence: [email protected] (O.M.); [email protected] (I.A.C.); Tel.: +40-745-279-714 (O.M.) Medical Student, University of Medicine and Pharmacy “Grigore T. Popa”, 700115 Iasi, Romania. y Academic Editors: Raluca Maria Pop, Ada Popolo and Stefan Cristian Vesa Received: 25 March 2020; Accepted: 7 April 2020; Published: 9 April 2020 Abstract: Micronutrients, especially vitamins, play an important role in the evolution of cardiovascular diseases (CVD). It has been speculated that additional intake of vitamins may reduce the CVD burden by acting on the inflammatory and oxidative response starting from early stages of atherosclerosis, when the vascular impairment might still be reversible or, at least, slowed down. The current review assesses the role of major vitamins on subclinical atherosclerosis process and the potential clinical implications in patients without CVD.
    [Show full text]
  • WCA Clinical Nutrition Module 1 Part 2
    Chiropractic Nutrition Module 1 Part 2 of 2 By: Chad Oler, ND WCA Clinical Nutrition: Module 1 Chad Oler, ND Chad Oler, ND ° Micronutrients ° Water soluble vitamins: RDAs, deficiency, toxicity ° Fat Soluble vitamins: RDAs, deficiency, toxicity ° Minerals: RDAs, deficiency, toxicity ° Metals: RDAs, deficiency, toxicity ° Phytonutrients ° Non-essential and conditionally essential nutrients ° Efficacy, safety, risks and benefits of glandular products and therapeutic enzymes ° Micronutrients ° Vitamins ▪ Water soluble – B, C ▪ Fat soluble – A, E, D, K ° Minerals ° Antioxidants ° Phytonutrients ° Amino acids ° Conditionally Essential Nutrients www.naturalpathhealthcenter.com 1 WCA Clinical Nutrition: Module 1 Chad Oler, ND ° Cannot be synthesized in sufficient quantities and must be obtained through diet ° Classified by their biological and chemical activity, not their structure ° Each “vitamin” refers to a number of vitamer compounds that all show the biological activity associated with a particular vitamin ° Each set of compounds is grouped under an alphabetized vitamin “generic descriptor” title ▪ “Vitamin A” includes retinal, retinol, and four known carotenoids. ° Vitamers by definition are convertible to the active form of the vitamin in the body and are sometimes inter- convertible to one another as well www.naturalpathhealthcenter.com 2 WCA Clinical Nutrition: Module 1 Chad Oler, ND ° Vitamin B1 –Thiamin ° Vitamin B2 – Riboflavin ° Vitamin B3 – Niacin ° Vitamin B5 – Pantothenic Acid ° Vitamin B6 – Pyridoxine ° Vitamin B7 - Biotin °
    [Show full text]
  • Compositions Comprising Nebivolol
    (19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser.
    [Show full text]
  • Growth of Bifidobacteria in Adults' Intestines on Oral Administration of Sugar Source, Pantethine and Riboflavin
    Bifidobacteria Microflora Vol. 3(1), 43-49, 1984 ORIGINAL Growth of Bifidobacteria in Adults' Intestines on Oral Administration of Sugar Source, Pantethine and Riboflavin Kouhei YAZAWA,1* Akiko NAKAJIMA1 and Zenzo TAMURA2 Department of Analytical Chemistry,Faculty of PharmaceuticalSciences , Universityof Tokyo, Hongo, Bunkyo-ku, Tokyo 113,1 and Keio UniversityHospital Pharmacy, Shinanomachi,Shinjuku-ku, Tokyo 1602 (Received 24 December, 1983) Among 45 Bifidobacteriumstrains of adult origin , all required a sugar source (ex. lactose) and pantethine (or pantothenic acid), 35 strains required riboflavin , and 12 required thiamine as essential nutrients . Fifteen strains were able to grow on pantothenic acid as well as pantethine. Fewer than 9 strains required other nutrients. The sugar source (10 to 15 g/day), pantethine (50 mg/day) and riboflavin (5 mg/day) were orally administered to 2 healthy adults whose proportion of bifidobacteria in the intestinal florae was usually very low (less than 1% of total bacterial number) . The sugar source was lactulose, raffinose or inulin. Pantethine and riboflavin were packed together in capsules and enteric-coated. Administration of both sugar source and vitamin capsules caused marked growth of bifidobacteria (more than 40% of total bacterial number) in both adults. Administration of the sugar source alone caused moderate growth of bifidobacteria (13%), while administration of the vitamin capsules alone was ineffective. These results indicate that the sugar source is es- sential for growth of bifidobacteria in adults, as well as in infants, and that adminis- tration of pantethine and riboflavin is important. Key words: Nutritional requirement; pantethine; riboflavin; sugar source; Bifi- dobacterium;lactulose; raffinose, inulin A great deal of investigation has been source in bottle-fed infants.
    [Show full text]
  • Vitamins and Minerals: a Brief Guide
    Vitamins and minerals: a brief guide A Sight and Life publication Vitamins and minerals: a brief guide Vitamins are organic nutrients that are essential for life. Our bodies need vitamins to function properly. We cannot produce most vitamins ourselves, at least not in sufficient quantities to meet our needs. Therefore, they have to be obtained through the food we eat. What are vitamins A mineral is an element that originates in the Earth and always retains its chemical identity. Minerals occur as inorganic crystalline salts. Once minerals enter the body, they remain there until and minerals? excreted. They cannot be changed into anything else. Minerals cannot be destroyed by heat, air, acid, or mixing. Compared to other nutrients such as protein, carbohydrates and fat, vitamins and minerals are present in food in tiny quantities. This is why vitamins and minerals are called micronutrients, because we consume them only in small amounts. Each of the vitamins and minerals known today has specific functions in the body, which makes them unique and irreplaceable. No single food contains the full range of vitamins and minerals, and inadequate nutrient intake results in deficiencies. A variety of foods is therefore vital to meet the body’s vitamin and mineral requirements. Of the known vitamins, four are fat-soluble. This means that fat or oil must be consumed for the vitamins to be absorbed by the body. These fat-soluble vitamins are A, D, E and K. The others are water-soluble: these are vitamin C and the B-complex, consisting of vitamins B1, B2, B6, B12, niacin, folic acid, biotin, pantothenic acid and choline.
    [Show full text]
  • The Truth About B-Vitamins
    THE TRUTH ABOUT B-VITAMINS EXPLORING A COMPLEX TOPIC FUNCTIONS SOURCES DEFICIENCIES THE TRUTH SERIES THE TRUTH SERIES As a discerning user of natural health products, you want what is best for your health. However, misinformation and deceptive marketing often make it challenging to TABLE OF CONTENTS identify fact from fiction. The Truth Series was created by Advanced Orthomolecular Research (AOR) to share the evidence-based truth about the most controversial and confusing topics within the natural health industry. At AOR, we believe that truth and transparency are the most important values for any organization to uphold. As visionaries, we are committed to continuous innovation so that we can advance the world of natural health. As such, the Truth Series aligns with our vision of providing optimal products without compromise. Published in Canada by: Advanced Orthomolecular Research Inc. Making Sense of B Vitamins 5 Managing Editor: Randall Heilik Vitamin B Deficiencies — Signs and Causes 12 Associate Editor: Justine Cooke Authors: Randall Heilik, CHNC, BCoMS, Scientific Consultant The Vital Role Vitamin B Plays in our Life Story 24 Dr. Navnirat Nibber ND, BSc, AOR Medical Advisor Dr. Aaron Zadek B.Sc. ND, Medical Advisor De-Mystifying Methylation 30 Dr. Robyn Murphy BSc, ND, Clinical Research Advisor B Vitamins: Myths and Controversies 40 Dr. Sarah Zadek, BSc. ND, Clinical Research Advisor Dr. Paul Hrkal, B.Kin ND, AOR Medical Director Nutrient spotlight: Pyrroloquinoline Quinone (PQQ) 48 Publication Design / Art Production: Laura Mensinga Creative Direction: Pix-l Graphx How to Get the B’s You Need 52 DISCLAIMER: The information in this publication is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment.
    [Show full text]
  • Establishing Tolerable Upper Intake Levels and a Risk Assessment
    Report of the Scientific Committee of the Food Safety Authority of Ireland The Safety of Vitamins and Minerals in Food Supplements – Establishing Tolerable Upper Intake Levels and a Risk Assessment Approach for Products Marketed in Ireland (Revision 2) Report of the Scientific Committee of the Food Safety Authority of Ireland The Safety of Vitamins and Minerals in Food Supplements – Establishing Tolerable Upper Intake Levels and a Risk Assessment Approach for Products Marketed in Ireland Published by: Food Safety Authority of Ireland Email: [email protected] Website: www.fsai.ie Join us on LinkedIn Follow us on Twitter @FSAIinfo Say hi on Facebook Visit us on Instagram Subscribe to our Youtube channel Originally published in 2018 Revision published in 2020 Applications for reproduction should be made to the FSAI Information Unit ISBN 978-1-910348-10-9 Report of the Scientific Committee of the Food Safety Authority of Ireland The Safety of Vitamins and Minerals in Food Supplements – Establishing Tolerable Upper Intake Levels and a Risk Assessment Approach for Products Marketed in Ireland CONTENTS ABBREVIATIONS 5 FOREWORD 6 EXECUTIVE SUMMARY 7 Recommendations ......................................................8 1. SAFETY OF VITAMINS AND MINERALS IN FOOD SUPPLEMENTS 11 1.1 Purpose of this Report . 11 1.2 Micronutrients ....................................................11 1.3 Vitamins . 11 1.4 Minerals and Trace Elements . 12 1.5 Dietary Reference Values ..........................................12 1.6 Sources of Intake..................................................16 1.7 Dietary Intakes in Ireland ..........................................17 1.8 Vitamins and Minerals: Relevant Food Legislation in Ireland . 20 1.9 Issues Arising Due to the Absence of Maximum Limits for Vitamins and Minerals added to Foods and used in Food Supplements .
    [Show full text]
  • Lessons Learned
    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
    [Show full text]
  • Why Supracaps?
    Why SupraCaps? FORMULA ! QUALITY ! CONVENIENCE ! VALUE FORMULA — 45 High Quality Ingredients, including: 18 Vitamins 11 Minerals 10 Fruit & Herb Extracts Alpha-Lipoic Acid CoQ10 Lutein Lycopene Quercetin Vinpocetine QUALITY All Ingredients at Meaningful Potencies Organic Mineral Chelates (not inorganic mineral salts) Standardized Fruit & Herb Extracts FDA registered and GMP Certified Facility (NSF International) CONVENIENCE Replaces Many Bottles of Supplements VALUE Save at Least 50% over Buying Supplements Separately The SupraCaps Formula VITAMINS. 7 CAPS 14 CAPS Vitamin A (vitamin A palmitate). 2,500 IU 5,000 IU Vitamin A (natural carotenes: alpha, beta, cryptoxanthin, zeaxanthin, and lutein). 5,000 IU 10,000 IU Vitamin D3 (cholecalciferol). 1,000 IU 2,000 IU Vitamin E (d-alpha tocopheryl succinate plus d-beta, d-delta, d-gamma tocopherols). 100 IU 200 IU Vitamin K (phytonadione and menaquinone-7). 60 mcg 120 mcg Vitamin C (ascorbic acid).. 500 mg 1,000 mg Vitamin B1 (thiamin HCl). 25 mg 50 mg Vitamin B2 (riboflavin). 25 mg 50 mg Vitamin B3 (niacin). 19 mg 38 mg Vitamin B3 (niacinamide). 56 mg 112 mg Vitamin B5 (d-calcium pantothenate). 50 mg 100 mg Vitamin B6 (pyridoxine HCl).. 25 mg 50 mg Vitamin B12 (methylcobalamin). 200 mcg 400 mcg Biotin. 300 mcg 600 mcg Folate (L-5-methyltetrahydrofolate).. 400 mcg 800 mcg Choline (bitartrate). 100 mg 200 mg Inositol. 100 mg 200 mg PABA (para-aminobenzoic acid). 25 mg 50 mg MINERALS Boron (aspartate-citrate).. 1 mg 2 mg Calcium (citrate-malate).. 200 mg 400 mg Chromium (nicotinate glycinate chelate). 100 mcg 200 mcg Copper (bisglycinate chelate).
    [Show full text]
  • Plant-Based Foods As a Source of Lipotropes for Human Nutrition: a Survey of in Vivo Studies Anthony Fardet, Jean-Michel Chardigny
    Plant-Based Foods as a Source of Lipotropes for Human Nutrition: A Survey of In Vivo Studies Anthony Fardet, Jean-Michel Chardigny To cite this version: Anthony Fardet, Jean-Michel Chardigny. Plant-Based Foods as a Source of Lipotropes for Human Nutrition: A Survey of In Vivo Studies. Critical Reviews in Food Science and Nutrition, Taylor & Francis, 2013, 53 (6), pp.535-590. 10.1080/10408398.2010.549596. hal-02648978 HAL Id: hal-02648978 https://hal.inrae.fr/hal-02648978 Submitted on 29 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Critical Reviews in Food Science and Nutrition For Peer Review Only Plant-Based Foods As a Source of Lipotropes for Human Nutrition: a Survey of In Vivo Studies Journal: Critical Reviews in Food Science and Nutrition Manuscript ID: Draft Manuscript Type: Review Date Submitted by the Version preprint Author: Complete List of Authors: Fardet, Anthony; INRA, Human Nutrition Keywords: Phytochemicals, lipotropes, hepatic steatosis, humans, rats URL: http://mc.manuscriptcentral.com/bfsnComment citer ce document : Email: [email protected] Fardet, A., Chardigny, J.-M. (2013). Plant-Based Foods as a Source of Lipotropes for Human Nutrition: A Survey of In Vivo Studies.
    [Show full text]
  • Subject Index to Abstracts
    003 1-3998/85/1904-44 lA$02.00 Vol. 19, No. 4, 1985 PEDIATRIC RESEARCH Printed in U.S.A. Copyright O 1985 International Pediatric Research Foundation,Inc. SUBJECT INDEX TO ABSTRACTS 1,25 (OH)2 D 1200 ADENOSINE DEAMINASE 909, 962, ALCOHOLISM 514 1,25 DIHYDROXYVITAMIN D3 973 967 ALDOSTERONE 333, 334, 808, 1,251 DIHYDROXYVITAMIN D 1223, ADENOSINE TRIPHOSPHATASE 323, 1591, 1605 1681 1571 ALKALINE PHOSPHATASE 728, 1200 14C DEOXYGLUCOSE 1316 ADENOSINE TRIPHOSPHATE 90, 98, ALKALOSIS 796 17 HYDROXYPROGESTERONE 436 860, 1600 ALKALOSIS, RESPIRATORY 1409 21 HYDROXYLASE DEFICIENCY 861 ADENOTONSILLECTOMY 1725 ALLERGY 652 21 HYDROXYLASE DEFICIENCY, ADENOVIRUS INFECTIONS 950 ALLOGENEIC 1018 NONCLASSICAL 861 ADENOVIRUSES, HUMAN 585 ALLOGRAFT REJECTION 1647 24 HOUR 440 ADENYL CYCLASE 277, 439, 1592 ALLOGRAFTS 1593, 1593 24 HYDROXYLASE RESPONSE 1200 ADHERENCE 880 ALMITRINE 837 25 (OH) D 1200 ADHESION 309 ALOPECIA 973 25 HYDROXYVITAMIN D 1 HYDROXYLASE ADHESIVE GLYCOPROTEINS 880 ALPHA 1-ANTITRYPSIN 1822 1223 ADIPOCYTE 713 ALPHA 1-ANTITRYPSIN DEFICIENCY 2H (OH) D 1200 ADIPOSE TISSUE 1187 813 3 BETAHYDROXYSTEROID ADIPOSITY 713 ALPHA FETOPROTEINS 1296, 1305 DEHYDROGENASE 431 ADOLESCENT BEHAVIOR 10, 19 ALPHA MANNOSIDASE 1241 3 METHYLGLUTACONIC ACID 823 ADOLESCENT PREGNANCY 20 ALPHA TOCOPHEROL 1466 3 METHYLGLUTACONIC ACIDURIA 823 ADRENAL 275, 334 ALTERNATE DAY STEROIDS 1726 3 METHYLGLUTARIC ACID 823 ADRENAL ANDROGEN SECRETION 480 ALTITUDE 273 4 CHANNEL PNEUMOGRAM 1523 ADRENAL CORTICOSTEROIDS 454 ALUMINUM 1595 5' NUCLEOTIDASE 881 ADRENAL HYPERPLASIA 431, 467 ALUMINUM
    [Show full text]